Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
Motoki MakuuchiYoichi KakutaJunji UmenoToshimitsu FujiiTetsuya TakagawaTakashi IbukaMiki MiuraYu SasakiSakuma TakahashiHiroshi NakaseHiroki KiyoharaKeiichi TominagaYosuke ShimodairaSakiko HiraokaNobuhiro UenoShunichi YanaiTakeo YoshiharaKazuki KakimotoKatsuyoshi MatsuokaRyohei HayashiSohachi NanjoItaru IwamaYoh IshiguroHirofumi ChibaKatsuya EndoTakashi KagayaTomohiro FukudaYasuhisa SakataTakahiro KudoTomohisa TakagiKenichi TakahashiMakoto NaganumaMasaru ShinozakiNoriyuki OgataHiroki TanakaKazuyuki NarimatsuHaruka MiyazakiTakashi IshigeMotoyuki OnoderaYu HashimotoHiroshi NagaiYusuke ShimoyamaTakeo NaitoRintaro MoroiHisashi Shiganull nullYoshitaka KinouchiAkira AndohTadakazu HisamatsuAtsushi MasamunePublished in: Journal of gastroenterology (2024)
NUDT15 codon 139 genotyping effectively reduces thiopurine-induced AEs and improves treatment retention rates in IBD patients after genotype-based dose adjustments. This study provides data-driven treatment strategies based on genotype and identifies risk factors for specific AEs, contributing to a refined thiopurine treatment approach.